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Calmodulin (CaM) is a calcium-binding protein that has promiscuous regulatory 
interactions with over three hundred intracellular protein targets. The focus of this study was to 
characterize the functional role of phosphorylated CaM in vitro and calcium-deficient CaM 
(Apo-CaM) ex vivo. In the in vitro study, the effect of phosphorylated CaM on the binding and 
activation of CaM target proteins was analyzed using mammalian Nitric Oxide Synthase (NOS). 
NOS is an enzyme that catalyzes the conversion of L-arginine to L-citrulline and •NO. In 
addition, the activation of NOS by modified CaM proteins was also analyzed in the presence of a 
CaM binding peptide, PEP-19. 
Protein trafficking experiments were performed ex vivo to extend our understanding of 
Apo-CaM’s functional role in mammalian cells. The cell lines that were used in this 
investigation include mouse Embryonic Stem Cells (mESC), Human Umbilical Vein Endothelia 
Cells (HUVEC) and Human Neuronal Glioma Cells (HNGC).  
The major finding of this projects are: phosphorylation of selective CaM residues can 
attenuated NOS activity, electrostatic interactions are important in the activation of iNOS by 
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 Literature review 
 
 
This section briefly covers the background information on the proteins, enzymes and 
peptides that were used in this thesis. The following are subjects covered in this introduction: 
Calmodulin (CaM), PEP-19, Nitric Oxide Synthase (NOS) isozymes and Cell Penetrating 
Peptides (CPP). 
 
1.1 Calmodulin   
1.1.1 Calmodulin 
CaM is a calcium sensing protein that plays an important role in important cellular 
processes such as apoptosis, cell proliferation, signal transduction, and gene transcription 
(Persechini et al., 1991; Ikura et al., 2006). Three hundred intracellular CaM-binding proteins 
have been identified including Myosin Light Chain Kinase (MLCK), ion transporters such as 
Inositol triphosphate (IP3), and NOS. In addition, CaM is the fifth most conserved mammalian 
protein (Ikura et al., 2006).  
As a result of the numerous target proteins and cellular pathways associated with CaM, a 
complete understanding of its functional role in the cell remains to be established. The numerous 
interaction of CaM makes it an appealing protein to investigate as one wonders how a single 
protein can selectively bind and/or activate so many proteins and cellular process simultaneously 





1.1.2 Structural features of CaM 
CaM is often described as a dumb-bell shaped structure connected by a central linker 
region (Yap et al., 2000). The conformation of CaM changes upon calcium induction; it exhibits 
an extended conformation in its Holo-form and a compact conformation in its Apo-form as 




Figure 1.1 - Crystal (A) and NMR (B) structures of CaM. (A) Apo-CaM (Kuboniwa et al., 
1995) PDB 1CFD, (B) Holo-CaM (Chattopadhyaya et al., 1992) PDB 1CLL. The white spheres 
represent calcium ions. The structural models were generated using ViewerLite 5.0 (Accelrys).  
 
 
The structural plasticity of CaM is supported by the existence of nine methionine residues 
and the presence of a flexible central linker. Typically, 1% of a protein's amino acid residues are 
methionine; however, 6% of CaM's amino acid residues are methionine. These methionine 




addition to methionine residues, the central linker helix enhances CaM's flexible nature by 
permitting the orientation of its two terminal domains to change independently. Therefore, CaM 
is able to accommodate a variety of different amino acid side chains in the target proteins (Trp, 
Phe, Ile, Val), thus allowing it to engage in a multiplicity of protein-protein interaction (Ikura et 
al., 2006; Spratt et al., 2008). 
   
1.1.3 Conformation of CaM when bound to a target protein  
NMR, X-ray crystallography and fluorescence-based methods have been employed to 
acquire detailed information on CaM's structural dynamics and protein-protein interactions with 
its target proteins. Such techniques include fluorescence polarization and Fluorescence (Förster) 
Resonance Energy Transfer (FRET), which can be used to monitor molecular domain 
interactions, mobility, enzyme function and changes in the intramolecular or intermolecular 
distances (Johnson, 2006; Spratt et al., 2006). Based on these studies, CaM has been shown to 
assume several different conformations when bound to target proteins such as the Myosin Light 







Figure 1.2 - Structural comparison of CaM binding conformations. Crystal representation of 
a) Ca2+-CaM (PDB 1CLL) b) CaM in complex with the MLCK peptide c) CaM in complex with 
the Ca2+ - activated K+ channel (PDB 1G4Y) and d) CaM in complex with the Oedema factor 
(PDB 1K93). The blue colored peptide is a representation of CaM-target peptide, while the green 
and the red colored protein regions represent CaM’s C-terminal lobe and N-terminal lobe, 
respectively. The yellow colored spheres are calcium ions. Models were generated using 
ViewerLite 5.0 (Accelrys). 
 
 
When bound to MLCK and the K+ ion channel, CaM assumes a compact conformation 
with the hydrophobic facets of CaM lobes surrounding the amphipathic target helix (Drum et al., 
2002). Intriguing, however, is the conformation of CaM when in complex with the Oedema 
factor, whereby it adopts an abnormal binding conformation; instead of CaM acting like a clamp 
and surrounding the target protein, the Oedema factor surrounds and binds to CaM. Post-
translational modification of CaM can to some degree modify its binding affinity to its target 
protein  
   
1.1.4 Ca2+- CaM  
The majority of CaM's target proteins are activated in a calcium-dependent manner. CaM 
contains four calcium binding EF-hand motifs, equally divided between the N-terminal and C-
terminal domains. The influx of calcium into the cytoplasm originates from either the 
extracellular space or from the intracellular reserves (rough endoplasmic reticulum).  It has been 
    a     Ca2+- CaM             b       CaM-MLCK                c       CaM-K+ channel                      d      CaM-EF 
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proposed that CaM, in its resting state, is bound to two Mg2+ ions within the N-terminal EF-hand 
pair, but the C-terminal EF-pair remains either metal free or calcium bound (Johnson, 2006). 
However, the Mg2+ ions are replaced with Ca2+ ions in response to elevated cytosolic Ca2+ 
concentrations (1-10 μM). In addition to Ca2+ ions, the activation of CaM-target proteins is also 
regulated by post-translational modifications of CaM itself (Gifford et al., 2007). 
  
1.1.5 Post-translational modification of Calmodulin 
  The interaction of CaM with certain target proteins can be regulated by modifying the 
CaM central linker region, residues 67-90. For instance, shortening the linker region can reduce 
the structural plasticity of CaM. In ex vivo, post-translation modifications of CaM, which include 
oxidation, acetylation, proteolytic cleavage, and phosphorylation, can serve as means of 
modulating CaM-target proteins, including NOS (Spratt et al., 2008). However, the effects of 
such modifications of CaM on CaM-target proteins remain to be fully investigated. Protein 
phosphorylation is one of the most common processes employed by mammalian cells to regulate 
various enzymatic activities and cellular processes. There is great interest in investigating the 
functional role of phosphorylated CaM in the modulation of cellular processes, such as cell 
proliferation. Interestingly, of 18 amino acid residues in CaM that have been proposed as 
candidates for phosphorylation, only 8 have been verified to undergo this process by known 





Figure 1.3 - Amino acid residues in CaM that have been shown to be phosphorylated in vitro 
and ex vivo (T79, S81, Y99 and S101). The blue regions are a representation of residues in CaM 
that can be phosphorylated by known kinases. The red and green regions represent the N- and C-
terminal domains, respectively. Yellow spheres represent calcium ions. The model (PDB 1CLL) 
was generated using ViewerLite 5.0 (Accelrys). 
 
The protein kinases that are known to phosphorylate CaM in vitro are listed in Table 1.1 
(Benaim et al., 2002). 
 
Table 1.1 – Known phosphorylation sites in mammalian CaM.  
Protein Kinase Phosphorylated residues 
Serine/threonine kinases  
   CK-II T79,S81,S101 (T117, *10%) 
   MLCK T29 (T26, *10%) 
Tyrosine kinases  
   InsR Y99 (Y138, *33%) 
   EGFRc-Src Y99 (Y138, *15%) 
   PTK-III (c-Fyn + C-Fgr) Y99 (Y138, *10%) 
   c-Src Y99 (Y138, *26%) 
* % of the residue in the parenthesis that was also phosphorylated by the same  











1.2 IQ domains and PEP-19  
PEP-19 protein, a member of small neuronal IQ motif proteins (SNIQP), is highly 
expressed in neuronal cells (~40 µM), particularly in Purkinje cells. This protein contains an 
acidic element and an IQ motif (IQXXXRXXXXX) that is recognized by Apo-CaM and Holo-
CaM (Slemmon et al., 1996). The IQ motif plays a key role in the binding of Pep-19 to CaM 
while the acidic element is essential in the modulation calcium binding to the C-domain of CaM 
(Putkey et al., 2003; Dickerson et al., 2006).  
The binding of PEP-19 to Apo-CaM is 30 times slower than it is to Holo-CaM. In 
addition, the binding of PEP-19 to CaM results in a 40- to 50-fold increase in the rate of calcium 
association and dissociation to CaM by changing the conformation of CaM’s C-domain. Such 
interaction is significant during signal transduction as the binding of calcium ions to CaM’s C-
terminal domain is too slow to respond to rapid transient calcium induction (Putkey et al., 2003). 
For simplicity, PEP-19 derived peptide (residues 28-62; Figure 1.4) will be referred to as 
Camstatin, hereafter. It is important to note that Camstatin will mimic the function of PEP-19 
(Putkey et al., 2008). 
 
 
Figure 1.4 – Amino acid sequence of Camstatin. The IQ motif is highlighted in blue and acidic 
element is exemplified by amino acid residues colored in red. The IQ motif is required for the 
binding of the peptide to CaM while the acidic element is needed for the modulation of calcium 
binding to CaM’s C-domain. 
 
PEP-19 (28-62)    EEFDIDMDAPETERAAVA   IQSQFRKFQKKKAG 
IQ Motif Acidic element 
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The ability of Camstatin to bind to both Apo-CaM and Holo-form is of great interest. It 
has been proposed that Camstatin sequesters free intracellular CaM and prevents it from 
associating with other target-proteins (Kubota et al., 2008). It has also been demonstrated that 
Camstatin can disrupt the activity of an enzyme in complex with CaM by directly associating 
with the enzyme’s bound CaM (Dickerson et al., 2006). Unlike other known neuronal CaM 
binding proteins that contain an IQ motif (such as neurogranin and neuromodulin), it is not 
known whether Camstatin is actually phosphorylated within the IQ domain as a regulatory step 
(Kubota et al., 2008). However, it has been determined that phosphorylation of PEP-19 on a 
serine residue outside of the IQ domain by serine/threonine kinase does indeed occur in vitro 
(Dickerson et al., 2006). In contrast to neuromodulin and neurogranin, such phosphorylation 
increases the affinity of Camstatin to CaM.  
With respect to NOS isozymes, PEP-19, at a 30-fold higher molar concentration to CaM, 
attenuates CaM-dependent nNOS activity (Slemmon, 1996). This may be physiologically 
relevant because, as stated before, the concentration of PEP-19 in certain neuronal cells is up to 
40-fold higher than that of CaM. Therefore, one of the objectives of this research project was to 
investigate NOS activation by CaM in the presence of Camstatin.  
 
1.3 Nitric Oxide Synthase 
  Nitric Oxide ( NO) plays an important role in blood vessel dilation, neurotransmission 
and immune response (Alderton et al., 2001). •NO is produced by Nitric Oxide Synthase (NOS), 
an enzyme that converts L-arginine and O2 into L-citrulline and •NO by way of two successive 
mono-oxygenation reactions (Spratt et al., 2006). 
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 In mammals, NOS enzymes exist as one of three different isoforms including neuronal 
NOS (nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS) (Yap et al., 2000; Spratt et 
al., 2006). These NOS isoforms differ in their expression and calcium dependence. While eNOS 
and nNOS are constitutively expressed and are Ca2+-CaM dependent enzymes, iNOS is inducibly 
expressed and binds to CaM in a Ca2+-independent manner (Spratt et al., 2007b). 
 
1.3.1 Structural features of NOS 
NOS is active in its dimer form with each monomer bound to L-arginine and five 
cofactors: FAD, FMN, Heme, Tetrahydrobiopterin (H4B), and NADPH (Johnson, 2006). Each 
monomer is composed of two functionally independent domains, an amino terminal oxygenase 
domain and a carboxy-terminal reductase domain, separated by a CaM binding motif (Figure 
1.5)  
 
Figure 1.5 - A general schematic presentation of NOS domains and sub-domains. The CaM 
binding site is located between the oxygenase and reductase domains. This figure is modified 
from Aldeton et al. (2001). 
 
The reductase domain contains a binding site for FAD, FMN, and NADPH cofactors, 
whereas heme, L-arginine, and H4B are localized in the oxygenase domain (Alderton et al., 
2001). The electron flow between the two domains is initiated when CaM binds to the 
amphipathic linker region of NOS, thus allowing for the production of •NO and L-citrulline 
 COOH 
CaM 
FMN FAD         NADPH Arg Heme H4B NH2 
Oxygenase Domain Reductase Domain 
Nitric Oxide Synthase 
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(Alderton et al., 2001; Spratt et al., 2006). The actual mechanism by which electrons are 
transferred between the two domains has not been fully established, but it is believed that the 
binding of CaM results in a major structural rearrangement of NOS, specifically within the FMN 
domain. It has been suggested that the FMN domain is highly dynamic due to a hinge region, 
thus, the binding of CaM to NOS is followed by the structural rearrangement of the FMN 
domain, permitting the delivery of electrons to the oxygenase domain (Ghosh et al., 2003). The 
electron transfer pathway in NOS commences in the reductase domain with the hydrogenation of 
NADPH. Subsequently, this process initiates a cascade of electron flow along the reductase 
domain involving the flavin cofactors and ending within the oxygenase domain. The transfer of 
electrons to the oxygenase domain is the rate liming step (Spratt et al., 2007a). Depending on the 
NOS isoform, this enzymatic process can be regulated in the cell by post-translational 
modifications (e.g. phosphorylation), heat shock protein 90, and by changes in the intracellular 
calcium concentration (Alderton et al., 2001).   
 
 
1.4 Cell penetrating peptides 
The introduction of therapeutics and reporter molecules across the plasma membrane 
requires an efficient delivery method. Traditional delivery methods such as microinjection, 
electroporation, chemical transfection, viral delivery systems, and liposome encapsulation have 
been used to introduce various cargo molecules into the cell (Trehin et al., 2004; Wadia et al., 
2005). However, all of these methods are prone to low internalization efficiency and high 
cellular toxicity. To characterize the functional role of Apo-CaM and phosphorylated CaM in the 
cell, a cell penetrating peptide (CPP) was used as a vector to deliver CaM protein into the cell.  
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CPPs are short (<30 amino acid) basic peptides capable of cell membrane permeation 
(Trehin et al., 2004; Wadia et al., 2005). Currents studies employ CPPs to introduce various 
cargo molecules into live mammalian cells. The cargo molecule, ranging from a nano particle to 
a protein, is generally coupled to the CPP by a covalent bond, such as a disulfide bond or a 
peptide bond (Fonseca et al., 2009). Such cargo molecules include DNA, metal particles, 
antibodies and proteins (Wadia et al., 2005). Over 10 different CPPs derived from either a 
synthetic or biological source are currently being used by research groups to study various 
cellular phenomena (Table 1.2). For example, clinical trials are underway for the treatment of 
Duchenne muscular dystrophy in the UK and the Netherlands. These research groups have 
introduced CPP attached phosphorodiamidate morpholino oligomer (~30-mer; CPP-PMO) by 
intramuscular injection in humans to target a mutated dystrophin exon, thereby restoring 
dystrophin to normal levels (Wu et al., 2008; Said Hassane et al., 2009). It is important to note 
that each CPP consists of a different translocation efficiency and cellular toxicity (Trehin et al., 
2004; Wadia et al., 2005).   
 
 Table 1.2 - A List of cell penetrating peptides (Said Hassane et al., 2009) 










 In this thesis, a CPP derived from Transactivator of Transcription protein (Tat peptide; 
see Table 1.2) of HIV-1 virus was chosen as a vector to introduce cargo molecules across the cell 
membrane due to its very high translocation efficiency and low cellular toxicity (Sugita et al, 
2008). The physiological effects and protein trafficking of Apo-CaM, excess wild-type CaM and 
CaM mutant proteins in the cell will be monitored by fluorescence microscopy. 
 
1.4.1 Transactivator of transcription peptide 
Transactivator of Transcription peptide (TAT) is a cell penetrating peptide derived from 
HIV-1 transactivator of transcription protein. TAT, an 11 amino acid basic peptide is composed 
of mainly arginine and lysine residues (YGRRKKRQRRR). The peptide itself contains two 
functional elements separated by a linker region (RQ). Each element has its own function; the N-
terminal element (YGRRKK) is essential for nuclear localization of the peptide, while the C-
terminal element (RRR) plays a pivotal role in the internalization of the peptide into the cell. 
Mutation or removal of any arginine residues in the peptide will reduce the internalization 
efficiency by 50% (Efthymiadis et al., 1998). The cargo-translocation delivery process employed 
by this peptide is yet to be determined as published data are plagued with artifacts. However, it 
has been hypothesized that TAT peptide permeates the cell membrane by one of the following 
delivery system: endocytosis, micelle-driven delivery, or by direct penetration of the plasma 






Figure 1.6- Proposed mechanisms of cargo delivery utilized by TAT peptide.  
Models 1 and 2 are reported to occur through an energy-receptor independent process, whereas 
model 3 occurs through an energy–receptor dependent process.  
 
 
The exact mechanism for cellular internalization of TAT peptide remains controversial. 
However, it has been suggested that the first step in the internalization process involves an 
electrostatic interaction between the positively charged residues of TAT and the negatively 
charged membrane constituents, such as proteoglycans, heparin and clathrin coated pits (Trehin 
et al., 2004; Tilstra et al., 2007). The subsequent step is the uptake of the cargo molecule by 
endocytosis or direct penetration of the cell membrane. Unfortunately, according to current 
literature, the majority of cargo molecules become trapped in the late endosome, only to be 
degraded in the lysosome if shuttling to the nucleus or release into the cytoplasm fails.  However, 
new methods have been developed to facilitate the release of trapped cargo molecules from 
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endosomes. For instance, the attachment of a poly-histadine tag on both sides of the TAT peptide 
will, to some extent, disrupt the endosomal membrane by dehydration to liberate trapped TAT 
from the endosome. The final destination of free TAT in the cell is the nucleus, where it will 
remain there for the duration of 24 hours before degraded. The method of utilizing CPPs to 
introduce cargo molecules into live cells can be applied for this ex vivo study to monitor the 



























 Regulation of mammalian nitric oxide synthase by electrostatic 






The promiscuity of CaM in its binding to numerous target proteins is due to the existence 
of a central linker region. The CaM central linker region acts as a flexible tether that permits 
variable orientation of the terminal domains in association with target proteins (Persechini et al., 
1988). The linker region can also undergo phosphorylation and other post-translational 
modifications within the cell (Benaim et al., 2002). The role of the central linker region and 
electrostatic interaction of CaM in the binding and activation of target proteins have been 
investigated using truncated CaM, charge substituted CaM (negative to positive) and 
phosphomimetic CaM mutants. Deletion of a single residue in the central linker region of CaM 
brings the two terminal domains closer to each other by 1.5 Å and alters the orientation of the 
lobes by 100º relative to one another (Persechini et al., 1989). Persechini et al. (1989) have 
reported changes in the activation profile of different CaM-target enzymes by central-linker 







The kinetics assays for cNOS enzymes with mutant CaM were performed by Spratt. The kinetics assays for iNOS 
enzyme with mutant CaM were performed by Israel. Circular dichroism experiments were performed by Israel. Gel 




 CaM residue E82, E83 and E84 are all negatively charged amino acids, which plays a key 
role in the association of CaM with its target proteins. Although the effect truncated CaM 
proteins (CaM Δ 81-84, Δ 83-84, Δ 84) on nNOS activity was analyzed, the activation profile for 
eNOS and iNOS with these mutants was unknown prior to our investigation. Our aim was to 
determine if the inactivation of NOS isozymes by central linker truncated CaM mutants were a 
result of changes in the electrostatic interaction within the CaM-NOS complex. Furthermore, a 
set of mutations in the CaM central linker region was introduced, whereby glutamates (E84 and 
E87) were substituted with positively charged amino acid residues (arginine and lysine) to 
investigate the importance of electrostatic interaction between the CaM linker region and NOS  
In addition, to study the role of phosphorylated CaM in the activation of NOS isozymes 
with respect to electrostatic interaction, phosphomimetic CaM mutants were generated. 
Phosphomimetic CaM mutants are modified CaM proteins with serine/threonine and tyrosine 
residues substituted with aspartic and glutamic acid, respectively (Figure 2.1.0). 
 
Figure 2.1.0- Schematic diagram illustrating phosphomimetic amino acid residues. 
Threonine, serine and tyrosine are substituted with aspartic or glutamic acid to mimic a 










 Aspartic and glutamic acid can imitate a phosphate ion in regards to the negative charge 
it possesses. Studies by (Greif et al., 2004)  have shown that phosphomimetic CaM proteins can 
mimic the functional role of  phosphorylated CaM. In their study, phosphorylated CaM S101 
attenuated eNOS activity by ~30% (Greif et al., 2004). However, the change in eNOS activity by 
phosphorylated CaM S101 was not addressed nor did the authors propose a mechanism to 
explain such attenuation. In contrast to attenuation of eNOS by phosphorylated CaM S101, the 
Carafoli group reported a 2.6-fold increase in nNOS activity by phosphorylated CaM catalyzed 
by Casein kinase 2 (CK-II) (Quadroni et al., 1998). Casein kinase 2 simultaneously targets CaM 
T79, CaM S81, and CaM S101 for phosphorylation (Quadroni et al., 1994). However, it was not 
determined which of these residues played a key role in the up-regulation of nNOS activity. 
Although extensive studies on eNOS activation by phosphorylated CaM have been published, 
the iNOS activation profile by phosphorylated CaM was unknown until now.  
In summary, a series of central linker CaM mutants was generated to investigate the 
importance of electrostatic interaction in the binding and activation of Ca2+- independent iNOS 
enzyme and Ca2+-dependent cNOS enzymes. 
 
 
2.2 Experimental procedures 
2.2.1 Mutations of CaM 
Vectors coding for phosphomimetic CaM mutants T79D, CaM S81D, CaM T79D/S81D, 
CaM S101D and CaM Δ84 in the kanamycin resistant pET9dCaM plasmid (Spratt et al., 2006) 
were developed using The QuikChange site-directed mutagenesis procedure (Wang et al., 1999). 
Vectors coding for truncated CaM mutants (Δ81-84, CaM Δ83-84, and Δ84 in pKK233-2) and 
charged CaM mutants (CaM E84R/E87K in pET23b) were generous gifts from Dr. John 
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Adelman (Oregon Health & Sciences University, Portland, OR, USA; (Lee et al., 2003) and Dr. 
Anthony Persechini (University of Missouri at Kansas City, MI, USA; (Persechini et al., 1989), 
respectively. PCR amplification was used to introduce NcoI and SacI cut sites in the pET28a 
(Novagen) vectors of CaM E84R/E87K, CaM Δ81-84 and CaM Δ83-84 DNA constructs. The 
primers that were used in the PCR mutagenesis and cloning of these vectors (CaM E84R/E87K, 
CaM Δ81-84 and CaM Δ83-84) are summarized in Table 2.1.0. 
 






2.2.2 CaM protein expression and purification 
Wild-type CaM and mutant CaM proteins were expressed and purified using affinity 
chromatography (phenyl sepharose), as previously described (Spratt et al., 2006). The purity of 







2.2.3 Binding of CaM central linker mutant proteins to synthetic NOS peptides 
Secondary structures of CaM in complex with NOS-CaM binding domains were analyzed 
using Circular Dichroism (CD). CD analysis was conducted with a Jasco J-715 CD 
spectropolarimeter, using J-715 analysis software as previously described (Spratt et al., 2007b). 
Prepared samples consisted of 10 µM wild-type CaM or mutant CaM proteins alone or with 
equimolar concentrations of synthetic NOS CaM-binding domain peptide. The NOS CaM-
binding domain peptides for bovine eNOS (TRKKT FKEVA NAVKI SASLM; residues 493–
512), rat nNOS (KRRAI GFKKL AEAVK FSAKL MGQ; residues 725–747), and human iNOS 
(RPKRR EIPLK VLVKA VLFAC MLMRK; residues 507–531) were synthesized by Sigma-
Genosys (Oakville, ON, Canada). Samples were mixed in a buffer consisting of 10 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 200 µM CaCl2, and 1 mM EDTA. Gel shift mobility assays were 
performed as previously described (Spratt et al., 2006).  
 
 
2.2.4 NOS expression and purification 
cNOS enzyme, rat nNOS and bovine eNOS were expressed as previously described 
(Roman et al., 1995; Martasek et al., 1996) with the exception that these constructs had an N-
terminal polyhistidine tail cloned upstream from their respective start codons. Human iNOS, 
carrying a deletion of the first 70 amino acids and an N-terminal polyhistidine tail, was co-
expressed with wild-type CaM or mutant CaM protein in E. coli BL21 (DE3) (Newman et al., 
2004). Ammonium sulfate precipitation, metal chelation chromatography, and 2’5’-ADP 
sepharose chromatography were employed to purify the NOS enzymes. iNOS was co-expressed 




2.2.5 Enzyme kinetics 
 The enzyme kinetics tools that were used to measure and monitor the electron transfer 
rates in the NOS are NADPH oxidation, cytochrome c reduction, and the oxyhemoglobin capture 
assays (Figure 2.1), as previously described (Gachhui et al., 1996; Montgomery et al., 2000; 
Montgomery et al., 2003; Spratt et al., 2007a).  Assays were performed in 96-well microtitre 
plates at 25 °C in a SpectraMax 384 Plus 96-well UV–visible spectrophotometer equipped with 
Soft Max Pro software (Molecular Devices, Sunnyvale, CA).   
 
 
Figure 2.1.1-Spectroscopic assays (in red color) that can be used to monitor electron flow 
and ·NO production within NOS. The NADPH assay measures the oxidation of NADPH .The 
ferricyanide assay measures the hydride transfer to the FAD. The cytochrome c assay 
measures electron transfer through the reductase domain to the FMN. The oxyhemoglobin 
(HbO4) capture assay measures the production of •NO from L-arginine. This figure was modified 




2.3.1 Characterization of mutant CaM proteins 
 Purification of CaM resulted in over 95% homogeneity, as judged by SDS-PAGE 
analysis (Figure 2.2). ESI-MS confirmed the actual molecular weight of CaM mutants to be the 
same as the theoretical size (Table 2.1). Structural data for CaM mutants obtained via CD 
analysis revealed that it was identical to wild-type CaM (wtCaM) in the presence of Calcium 
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ions and EDTA, with respect to its alpha-helical content. CD analysis revealed no significant 
change in the alpha-helical content when compared to wtCaM in the presence of calcium for 
CaM mutants (truncated, charged and phosphomimetic mutants) in complex with the cNOS, 
eNOs and nNOS, CaM- binding peptide. However, there were significant changes in the 
secondary structure of iNOS peptide bound to CaM mutants in the presence of EDTA (CaM 81-
84, CaM E84R/E87K), where a decrease in alpha-helical content was observed (Figure 2.3). Gel 
shift mobility analysis for all CaM mutants in complex with NOS-CaM binding domain peptides 
showed an association ratio of 1:1. 
.  
  
Figure 2.2 – 15% SDS-PAGE analysis of purified CaM proteins. A 10 μg sample of each 
purified CaM protein was loaded in a standard SDS-PAGE loading buffer containing 1 mM 
EDTA. Lane 1, low molecular mass protein standard (GE Healthcare); Lanes 2 & 8, wild-type 
CaM; Lane 3, CaM T79D; Lane 4, CaM S81D; Lane 5, CaM T79D/S81D; Lane 6, CaM S101D; 











Table 2.1.1 – Masses of phosphomimetic/charged and central linker  
deletion CaM proteins 
      
                      Mass (Da) a 
     
     
  Observed Theoretical b 
 CaM proteins     
   
Wild-type CaM 16706.0 16706 
   
Phosphomimetic  /Charge CaMs   
CaM T79D 16718.5 16720 
CaM S81D 16731.5 16734 
CaM T79D/S81D 16746.5 16748 
CaM S101D 16732.5 16734 
CaM E84R/E87K 16730.5 16733 
   
Central Linker Deletion CaMs   
CaM Δ84 16575.0 16577 
CaM Δ83-84 16446.0 16448 
CaM Δ81-84 16230.0 16232 
   
a Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 5 Da. 
b Calculated masses based upon amino acid sequence. 
 
   
Figure 2.3 - Difference CD spectra for iNOS CaM binding domain peptides bound to wild-
type CaM and mutant proteins. Difference spectra for the iNOS peptide were calculated by 
subtracting the spectra of 10 μM CaM in the presence of EDTA from the spectra of 10 μM CaM 
in the presence of 10 μM peptide and EDTA. Difference spectra are represented as shown in 
parenthesis: wild-type CaM (----), CaM Δ81-84 (─ ─), CaM E84R/E87K (─), and iNOS peptide 





2.3.2 Effect of phosphomimetic and charge mutant CaM proteins on NOS activation 
The rate of in •NO production measured from the oxyhemoglobin assay marked a 
decrease in iNOS catalytic activity of 10-20 % by phosphomimetic CaM (Table 2.2). The 
addition of excess EDTA in the presence of wtCaM and phosphomimetic CaM mutants (with 
exception to CaM E84R/E87K) resulted in slight reduction of iNOS activity, which is consistent 
with previous studies (Venema et al., 1996; Newman et al., 2004; Spratt et al., 2006; Spratt et 
al., 2007a). However, the activity of iNOS was significantly reduced by CaM E84R/E87K in 
comparison to wtCaM and phosphomimetic mutants. In addition, a Ca2+-dependent activation of 
iNOS is observed in the presence of 250 µM EDTA (Table 2.2).   
 
Table 2.2– Phosphomimetic/charged and central linker mutant CaM protein activation of 
iNOS a 
  NADPH oxidation Cyt c reduction ●NO synthesis  
CaM protein 200 µM 250 µM 200 µM 250 µM 200 µM 250 µM 250 µM EDTA 
CaCl2 EDTA CaCl2 EDTA CaCl2 EDTA with 3 µM CaM 
  % % % % % % % 
              
CaM  100 ± 3 86 ± 4 100 ± 4 84 ± 5 100 ± 4 87 ± 2 82 ± 2 
             
Phosphomimetic  /Charge 
CaMs            
CaM T79D 106 ± 1 95 ± 2 120 ± 4 108 ± 5 82 ± 2 62 ± 3 74 ± 3 
CaM S81D 104 ± 1 103 ± 3 169 ± 3 170 ± 5 91 ± 3 74 ± 3 77 ± 3 
CaM T79D/S81D 102 ± 1 98 ± 3 149 ± 1 130 ± 2 90 ± 3 81 ± 3 84 ± 4 
CaM S101D 103 ± 3 97 ± 3 153 ± 3 154 ± 2 88 ± 1 68 ± 1 75 ± 2 
CaM E84R/E87K 101 ± 1 52 ± 1 133 ± 1 108 ± 3 71 ± 1 7 ± 1 50 ± 2 
             
Central Linker Deletion CaMs            
CaM Δ84 110 ± 5 109 ± 5 160 ± 4 147 ± 3 64 ± 3 20 ± 1 48 ± 2 
CaM Δ83-84 124 ± 4 120 ± 3 160 ± 3 154 ± 1 65 ± 3 9 ± 1 51 ± 2 
CaM Δ81-84 116 ± 3 103 ± 3 134 ± 3 120 ± 2 67 ± 3 5 ± 1 50 ± 2 
               
a •NO synthesis, cytochrome c reduction and NADPH oxidation rates were measured with no exogenous CaM added to 
the assay.  Each assay was performed in the presence of either 200 µM CaCl2 or 250 µM EDTA as indicated.  The activities 
obtained for iNOS coexpressed with CaM and assayed in the presence of 200 µM CaCl2 at 25oC were all set to 100% and were 






Both cytochrome c reduction rates and NADPH oxidation rates for iNOS co-expressed 
phosphomimetic CaM proteins were slightly higher in comparison to wild-type CaM in the 
presence of calcium ions. However, chelation of calcium ions resulted in a decreased of both 
cytochrome c reduction rates and NADPH oxidation rates for iNOS co-expressed with 
phosphomimetic CaM proteins (Table 2.2). 
 Unlike iNOS, the eNOS enzyme maintained a 100% activity when in complex with 
phosphomimetic CaM mutants, with exception to CaM S101D, a 20% decrease in eNOS enzyme 
activity is observed. In addition, charge CaM mutant protein reduced eNOS activity by 74%.  
Data extracted from NADPH oxidation and cytochrome c reduction assays presented a similar 
trend for eNOS activation with each CaM mutant.  
A slight attenuation nNOS activity was observed by all phosphomimetic CaM proteins by 
a decrease in •NO production.  This data is supported by previous studies where differences 
between eNOS and nNOS activation profiles, using a variety of CaM mutants, were observed 
(Montgomery et al., 2003; Newman et al., 2004; Spratt et al., 2006).  Similarly to eNOS and 
iNOS, the •NO production rate for nNOS in complex with CaM E84R/E87K was significantly 
















Table 2.3 – CaM phosphomimetic/charged and central linker deletion mutant dependent 
activation of cNOS enzymes a 
  Neuronal NOS Endothelial NOS  
 NADPH Cyt c ●NO NADPH Cyt c ●NO 
CaM protein Oxidation Reduction Production Oxidation Reduction Synthesis
  % % % % % % 
              
CaM  100 ± 4 100 ± 3 100 ± 2 100 ± 1 100 ± 4 100 ± 2 
CaM (EDTA) 13 ±  4 9 ± 1 NAAb 15 ± 3 9 ± 3 NAA 
           
Phosphomimetic  /Charge 
CaMs           
CaM T79D 93 ± 3 105 ± 3 94 ± 3 105 ± 3 86 ± 4 108 ± 3 
CaM S81D 89 ± 5 106 ± 5 89 ± 3 107 ± 4 84 ± 5 106 ± 2 
CaM T79D/S81D 97 ± 2 111 ± 2 76 ± 3 99 ± 2 80 ± 1 102 ± 3 
CaM S101D 80 ± 3 99 ± 3 80 ± 2 100 ± 2 86 ± 4 82 ± 5 
CaM E84R/E87K 39 ±  2 31 ± 1 44 ± 3 30 ± 1 18 ± 4 26 ± 3 
           
Central Linker Deletion CaMs           
CaM Δ84 86 ± 3 114 ± 6 101 ± 1 86 ± 5 77 ± 2 80 ± 2 
CaM Δ83-84 77 ± 3 118 ± 2 105 ± 3 89 ± 7 92 ± 3 79 ± 1 
CaM Δ81-84 82 ± 1 96 ± 2 88 ± 7 58 ± 4 49 ± 4 57 ± 3 
              
a The oxyhemoglobin capture assay used to measure the rate of CaM-activated •NO production, the cytochrome c assay and the 
NADPH oxidation assay were performed in the presence of either 3 µΜ wild-type or mutant CaM protein and either 200 µM 
CaCl2 or 250 µM EDTA, as indicated.  The activities obtained with the respective enzyme bound to wild-type CaM at 25oC in the 
presence of 200 µM CaCl2 were all set to 100%.  The activities for nNOS bound to CaM were 36 min-1 (•NO synthesis), 132 min-
1 (NADPH oxidation) and 1253 min-1 (cytochrome c reduction).  The activities for eNOS bound to CaM were 9 min-1 (•NO 
synthesis), 27 min-1 (NADPH oxidation) and 71.1 min-1 (cytochrome c reduction). The standard deviation was calculated from 
data obtained in quadruplicates.  
b NAA – No apparent activity 
 
 
2.3.3 Effect of CaM central linker deletion mutations on CaM-dependent NOS activation 
A 35% decrease in •NO synthesis from iNOS enzyme was detected when in complex 
with all of the truncated-central linker CaM mutants (Table 2.2). Interestingly, the addition of 
EDTA to the system resulted in the attenuation of •NO synthesis when iNOS was in complex 
with each truncated CaM mutant, indicating Ca2+-dependent activation. However, the addition of 
excess wild-type CaM was able to maintain iNOS enzyme activity.    
 A decrease in NADPH oxidation or cytochrome c reduction rate was not observed upon 
removal of residues in the central linker of CaM. These  kinetic results indicate that electron 
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transfer within iNOS is controlled primarily in the FMN domain, transferring electrons to the 
catalytic heme in the oxygenase domain (Feng et al., 2006).   
Unlike the iNOS enzyme, eNOS and nNOS enzymes displayed similar, but not 
equivalent activation profiles when associated with these three central linker deletion CaM 
mutants. Shortening the CaM linker region resulted in a slight decrease in eNOS’s •NO 
production by 20-50% (Table 2.3). For nNOS, only CaM Δ81-84 decreased •NO synthesis by 
12% when compared to wtCaM. These data are consistent with previous published work, where 
the activity of various CaM-dependent enzymes were attenuated with the deletion of each 
residue in the central linker region of CaM (Persechini et al., 1989). Likewise, nNOS reductase 





Using  solved crystal-structures of CaM-eNOS peptide (Aoyagi et al., 2003) and CaM-
nNOS peptide (Ng et al., PDB 2O60), we were able to provide some proposition for the effects 
that these CaM mutant proteins have on their association to eNOS and nNOS (Figure 2.4). In 
terms of eNOS and nNOs, phosphomimetic CaM S101D presented the most significant decrease 
in catalytic activity; however, this residue does not appear to have any direct interaction with the 
CaM-binding domain of eNOS and nNOS.  It is plausible that this residue maybe be associating 
with a residue in the flanking region of cNOS. In addition, nNOS also demonstrated a decrease 
in activation with CaM T79D/S81D.  Both of these residue form hydrogen bond with K743 of 





Figure 2.4- Structure of Ca2+-replete wild-type CaM and sequence alignment of the CaM-
binding domains of the NOS enzymes. (A) The peptide backbone of CaM is shown in blue. The 
mutation sites in CaM used in this study are highlighted to demonstrate their respective locations in CaM 
T79 (red), S81 (pink), E84 (cyan), E87 (green) and S101 (yellow). (B) Hydrophobic residues found in the 
NOS CaM-binding motif 1-5-8-14 are highlighted. Acidic and basic residues found in the NOS CaM-
binding domains are shown in red and blue, respectively. The model (PDB 1CLL) was generated using 
ViewerLite 5.0 (Accelrys).  
  We do not suspect electrostatic interaction between CaM T79D/S81D and nNOS to be 
the cause of this attenuation. However, we do believe that changes in conformation of CaM’s 
linker region by phosphorylation prohibit optimal association of CaM to the CaM-binding 
domain of nNOS. 
 CaM E84R/E87K appears to have the greatest effect on cNOS marked by significant 
attenuation of the enzyme activity. With respect to eNOS, CaM E84 interacts with K504 of 
bovine eNOS CaM-binding domain (positions 9) while E87 of CaM interacts with V503 and 
S508 of eNOS (positions 8 and 13). Consequently, electrostatic repulsion would exist when CaM 
E84, which interacts with a positive residue K504, is substituted with an arginine residue. In 
contrast, both E84 and E87 of CaM form hydrogen bonds with Q747 of nNOS (position 17). The 
only plausible explanation that we can think of that can lead to such attenuation of nNOS activity 
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by this charged CaM mutant would be the weakening of association between CaM and nNOS by 
the removal of hydrogen bonds. 
Therefore, using both solved crystal structures of CaM bound to eNOS (Aoyagi et al., 
2003) and nNOS (PDB 206O) in conjunction with  alignment of the NOS CaM-binding domains 
(Figure 2.4), we have been able to determine the cause of iNOS activity by the current CaM 
mutants protein.  All of the phosphomimetic CaM proteins attenuated iNOS activity; however, 
based on the alignment of the NOS CaM-binding domain, we suspect that changes in CaM 
conformation could have destabilized the interaction between NOS and CaM and that 
electrostatic interaction is disrupted. This can be justified as T79 and S81 of CaM would likely 
interact predominantly with hydrophobic residues in the human iNOS CaM-binding domain 
(V522, L523, C526, and M527 as shown in Figure 2.4).  Similar to the cNOS enzymes, S101 of 
CaM would most likely have no direct interaction with the CaM-binding domain of iNOS, but 
instead with flanking regions in the reductase/oxygenase domain, as previously suggested (Ruan 
et al., 1996).   
The observed NOS Ca2+-dependent activation of cNOS and iNOS by CaM E84R/E87K 
can be related to a combination of hydrophobic and electrostatic forces. We have mentioned in 
the result section that E84 and E87 have been shown to interact with Q747 of rat nNOS, using 
the alignment in Figure 2.4 B. This residue, Q747 of nNOS, correspond to a lysine in the iNOS 
CaM-binding domain (K531, Figure 2.4 b). Therefore, substitution of a CaM E84 and E87 with 
positive charge residues will cause a significant electrostatic repulsion between the two proteins. 
However, this repulsion appears to be hindered by hydrophobic interaction between CaM and 
NOS in the presence of calcium. Thus, the introduction of EDTA to chelate calcium ions from 
 
 29 
CaM weakens the hydrophobic interactions with iNOS that is necessary to overcome the 
repulsion interaction between K531 (iNOS) and CaM E84R/E87K. 
In conclusion, this study has determined that in addition to hydrophobic interactions, 
electrostatic interaction plays a key role in the Ca2+-independent association of CaM to iNOS.  
This was accomplished by using a series of CaM mutants where charged residues in the 
glutamate rich central linker region (residues 82-87) were removed (ex. CaM Δ 81-84), added 
(CaM S81D) or substituted (CaM E84R/E87K) to measure electron transfer and •NO production 



















The effect of Camstatin and Phosphorylated CaM on the activity of 
Nitric Oxide Synthase 
 
3.1 Introduction 
Phosphorylation of CaM results in the activation and modulation of different signal 
cascades and enzymatic activities within the cell. It has been reported that phosphorylation of 
S101 of CaM attenuates eNOS activity by 30% (Spratt et al., 2008). On the other hand, CaM 
phosphorylated (CaM residues T79, S81, S101) by CK-II increases nNOS activity by 300% 
(Quadroni et al., 1998). To date, only 3 (T79, S81, S101) of the 6 amino acid residues within the 
central linker region and the C-terminal region of CaM that serve as candidates for 
phosphorylation have been extensively investigated with respect to NOS activity. The present 
thesis expands on this research by investigating two additional CaM residues that can undergo 
phosphorylation, Y99 and Y138. These residues are located in the C-terminal domain, in close 
proximity to the calcium-binding motif. Phosphorylation of Y99 can play an important role in 
the modulation of cellular process. For example, Y99 undergoes phosphorylation during hypoxia 
in the cerebral cortex of newborn piglets in response to increased •NO production by nNOS 
(Mishra et al., 2009a). The authors speculated that the increase in Y99 phosphorylation mediated 
by •NO serve as a means to up-regulate NOS activity by increasing the affinity of CaM to nNOS.  
  The project was further expanded by introducing an additional element thought to interact 
with CaM, Camstatin (Pep-19 peptide, see section 1.2 for details). It has been demonstrated that 
Camstatin, at high concentrations, attenuates nNOS activity (Slemmon et al., 1996); however, no 
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current study has evaluated its effect on the eNOS and iNOS isozymes. It is possible that the 
binding of Camstatin to CaM, in complex with iNOS, may result in the displacement of calcium 
ions in the CaM C-terminal domain and thereby inhibit iNOS activity. Thus, the phosphorylation 
of CaM may indirectly serve as a docking element for the binding of Camstatin to CaM in 
complex with NOS, as shown in Figure 3.1.  
 
 
Figure 3.1- Proposed mechanism for NOS inhibition by Camstatin after CaM 
phosphorylation. Red lines with a green caps that are attached to CaM are a representation  




The aforementioned hypotheses were examined by generating 6 phosphomimetic CaM 
proteins: Y99E, Y138E, Y99E/138E, Y99E/138E/S101D, Y99E/S101D, Y138/S101D, and 
T79D/S81D/S101D. It is important to note that some combinations of these residues are also 
phosphorylated by the same kinase in vitro (see table 1.1).  NOS activity was monitored using 
the oxyhemoglobin capture assay, the cytochrome c reduction assay, and the NADPH oxidation 
assay (see Figure 2.1). Thereby, the effects of phosphomimetic CaM proteins in conjunction with 
Camstatin were analyzed based on the activation of NOS. 
Camstatin (Pep-19) 
Attenuation of NOS activity 
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3.2 Experimental procedures  
 
3.2.1 Mutation of CaM proteins 
Vectors (kanamycin resistant pET9d plasmid) coding for phosphomimetic CaM mutant 
proteins Y99E, Y138E, S101D/Y99E, CaM S101D/Y138E, Y99E/Y138E, Y99E/S101D/Y138E 
and T79D/S81D/S101D were generated using the QuikChange site-directed mutagenesis 
procedure (Wang et al., 1999). The primers used in the PCR mutagenesis and cloning reactions 
for the development of these vectors (CaM mutant Y99E, Y138E, S101D/Y99E, CaM 
S101D/Y138E, Y99E/Y138E, Y99E/S101D/Y138E and T79D/S81D/S101D) are listed in the 
Table 3.1.0. Substitution of Tyr, Ser and Thr residues with negatively charged amino acids 
faithfully mimic the effect of a phosphate ion with respect to charge (Greif et al., 2004).  
 
 
Table 3.1.0- Primers used for CaM mutagenesis 
CaM protein Primer DNA Sequence 
Mutagenesis   




CaM Y138E PCaMT138Efr 
PCaMT138Erv 
5’ GGGGATGGTCAGGTTAACGAGGAAGAGTTTGTA 
5’ TACAAACTCT TCCTCGTTAA CCTGACCATCCCC 
CaM Y99E/S101D PCaMS101D447fr 
PCaMS101D447rv 
5’ AAGCTCTGCT GCATCGATCT CGCCATTGCC 




3.2.2 CaM protein expression and purification 
Wild-type CaM and mutant CaM proteins were expressed and purified using affinity 
chromatography (phenyl sepharose), as previously described (Spratt et al., 2006).  The 
concentration of CaM was determined using protein quantification Lowry Assay. The purity of 





3.2.3 NOS expression and purification 
cNOS enzymes, rat nNOS and bovine eNOS, were expressed as previously described 
(Roman et al., 1995; Martasek et al., 1996), with the exception that these constructs had an N-
terminal polyhistidine tail cloned upstream from their respective start codons. Human iNOS with 
the deletion of the first 70 amino acids and an N-terminal polyhistidine tail was co-expressed 
with wild-type CaM or mutant CaM Y99E protein in E. coli BL21 (DE3) (Newman et al., 2004). 
Ammonium sulfate precipitation, metal chelation chromatography, and 2’5’-ADP sepharose 
chromatography were employed to purify the NOS enzymes as previously described by Dr. 
Donald E. Spratt (Spratt et al., 2006).  
 
3.2.4 Enzyme kinetics 
The assays utilized to measure and monitor the electron transfer rates in NOS included, 
NADPH oxidation, cytochrome c reduction, and the oxyhemoglobin capture assay, as previously 
described (Gachhui et al., 1996; Montgomery et al., 2000; Montgomery et al., 2003; Spratt et al., 
2007a).  Assays were performed in 96-well microtitre plates at 25 °C. Spectral data was recorded 
using a SpectraMax 384 Plus 96-well UV–visible spectrophotometer and Soft Max Pro software 
(Molecular Devices, Sunnyvale, CA).   
 
3.2.5 Gel shift mobility assay  
 
Native Gel (15%) mobility shift assays (Sigma Technical Bulletin No. MKR-137, 1986) 
were performed to study the binding of Camstatin (PEP-19 peptide) with various CaM proteins. 
Protein interaction between the peptide and CaM is observed as a shift in the mobility of the 
CaM protein with increasing peptide concentration. In a total volume of 30 μL, wild-type CaM 
and CaM T79S/S81D (40 μM) were incubated with increasing molar ratios of Camstatin peptide 
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to CaM protein (0, 1, 4, 8, 15, 29) in binding buffer (100 mM Tris-HCl, pH 7.5, and 0.2 mM 
CaCl2) at room temperature for 1 hour. Similarly, wild-type CaM and CaM S101D (20 μM) were 
incubated with increasing molar ratios of Camstatin peptide to CaM protein (0, 0.25, 0.5, 0.75, 
1.0, 1.5, 4, 8). At completion of the incubation period, half the volume of each sample was 
combined with an equal volume of loading buffer, consisting of 50% glycerol and bromophenol 
blue as a tracer. The sample preparations were then electrophoresed through a 15% non-
denaturing polyacrylamide gel containing 0.375 M Tris-HCl, pH 8.8, 4 M urea, and 0.2 mM 
CaCl2. Gels were run at a constant voltage of 100 V in electrode running buffer consisting of 25 
mM Tris-HCl, pH 8.3, 192 mM glycine, 4 M urea, and either 0.2 mM CaCl2. The gels were then 




3.3.1 Protein expression and purification 
The final yield of purified phosphomimetic CaM protein was between 10-20 mg/L of 
medium.  Each mutant was found to be about 95% homogeneous based on SDS-PAGE analysis 
(Figure 3.1.1). Electrospray Ionization-Mass Spectrometry was also conducted to confirm the 








Figure 3.1.1 – 15% SDS-PAGE analysis of purified phosphomimetic CaM proteins. 
A 40 μg sample of each purified CaM protein was loaded in a standard SDS-PAGE loading. 
Lane 1, low molecular mass protein standard(GE Healthcare); Lanes 2 CaM Y99E; Lane 3, CaM 
Y138E; Lane 4, CaM Y99E/Y138E; Lane 5, CaM Y99E/S101D; Lane 6, CaM Y138E/S101D; 
Lane 7, CaM Y99E/S101D/Y138E. 
 
 
Table 3.1.1- Masses of phosphomimetic CaM proteins. 
      
                      Mass (Da) a 
     
     
  Observed Theoretical b 
 CaM proteins     
   
Wild-type CaM 16709 16709 
   
Phosphomimetic CaM   
CaM Y99E 16672 16675 
CaM Y138E 16672 16675 
CaM Y99E/Y138E 16640 16641 
CaM Y99E/S101D 16700 16703 







   
a Masses of deconvoluted ESI-MS spectra were determined with an accuracy of ± 5 Da. 




3.3.2 cNOS activation by phosphomimetic CaM 
The oxyhemoglobin capture assay was performed for eNOS and nNOS enzymes to assess 
the effects that phosphomimetic CaM mutants may have on their activity. The activity of nNOS 
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associated with each of the phosphomimetic CaM proteins was compared to the relative activity 
of nNOS in complex with wild-type CaM. Phosphorylation of CaM significantly modified nNOS 
activity, ranging from 30% to 125%, depending on the specific phosphomimetic CaM protein 
(Table 3.2). For instance, phosphomimetic CaM Y99E and Y138E resulted in a decrease of 
nNOS catalytic activity by over 50% when compared to wild-type CaM (Table 3.2). Meanwhile, 
an increase of nNOS by activity  by 25%was observed with phosphomimetic CaM Y99E/S101D 
and S101D/Y138E. Unlike their effect on nNOS activity, phosphomimetic CaM proteins 
consisting of a S101D mutation in combination with an Y99E and/or an Y138E mutation caused 
a decrease in ●NO production by eNOS that was two-fold. This result suggests a difference in 
phosphorylated CaM activation of eNOS and nNOS. Data obtained from the NADPH oxidation 
and cytochrome c reduction assays reveal that a reduction in the electron transfer rates within the 
reductase domain does not occur (Table 3.2). This result implies that a decrease in •NO 
production by cNOS is due to changes in electron transfer to the oxygenase domain from the 












 Table 3.2- Phosphomimetic CaM mutant dependent activation of cNOS enzymes 
  Neuronal NOS Endothelial NOS  
 NADPH Cyt c ●NO NADPH Cyt c ●NO 
CaM protein Oxidation Reduction Production Oxidation Reduction Synthesis 
  % % % % % % 
              
Wt CaM 100 ± 7 100 ± 3 100 ± 2 100 ± 1 100 ± 4 100 ± 1 
CaM (EDTA) 15 ± 4 9 ± 1 NAAb 15 ± 3 9 ± 3 NAAb 
           
Phosphomimetic CaM           
CaM Y99E 106 ± 3 109 ± 2 37 ± 5 93 ± 5 83 ± 2 31 ± 4 
CaM Y138E 94 ± 2 103 ± 3 68 ± 4 101 ± 3 75 ± 4 90 ± 1 
CaM Y99E/S101D 111 ± 2 96 ± 5 127 ± 3 86 ± 5 98 ± 3 50 ± 3 
CaM Y138E/S101D 115 ± 3 102 ± 2 125 ± 5 96 ± 4 98 ± 5 82 ± 1 
CaM Y99E/Y138E 99 ± 5 101 ± 4 98 ± 5 92 ± 5 98 ± 3 45 ± 5 
       
CaM Y99E/S101D/Y138E 97 ± 4 94 ± 3 77 ± 3 103 ± 1 98 ± 5 47 ± 2 
              
The standard deviation was calculated from data obtained in quadruplicates.  
bNAA- No Apparent Activity 
 
3.3.3 A gel shift mobility assay of CaM proteins with Camstatin  
 
Gel shift mobility assays were performed to investigate the binding of wild-type CaM 
and phosphomimetic CaM proteins to Camstatin. A shift in the mobility of wild-type CaM 
protein with increasing peptide concentration was observed. Weak interactions were detected 
between Camstatin and wild-type CaM, as well as two of the CaM mutant proteins, T79D/S81D 
and S101D (Figure 3.2). Future gel shift mobility assays should include Camstatin and other 
phosphomimetic CaM proteins, such as CaM Y99E and Y138E, to fully assess whether these 







Figure 3.2- Gel shift mobility assay of Camstatin binding to CaM proteins. 
A) Wild-type CaM (Wt CaM) (20 μM) and CaM T79D/S81D (20 μM) incubated with increasing 
molar ratios of Camstatin peptide to CaM (0, 1, 4, 8, 15, 19, and 29) in the presence of 0.2 mM 
CaCl2. B) Wild-type CaM (20 μM) and CaM S101D (40 μM) incubated with increasing molar 
ratios of Camstatin peptide to CaM (0, 0.25, 0.5, 0.75, 1, 1.5, 4, and 8) in the presence of 0.2 mM 
CaCl2. Protein separation shown on Native-PAGE (15% acrylamide) containing 0.375 M Tris, 





3.4 Discussion  
 
The phosphorylation of CaM proteins is an important post-translational modification that 
has been shown to mediate a number of critical intracellular processes (Spratt et al, 2008) Hence, 
it is of great interest to determine the implications phosphorylated CaM may have on the 
activation of NOS enzymes. In the present study, data obtained using phosphomimetic CaM 
proteins indicates that phosphorylation of CaM Y99 residue attenuates nNOS and eNOS activity 
Wt CaM CaM T79D/S81D 
0       1        4        8       15      19       29 0         1          4        8       15       19       29 
Camstatin + CaM 
 
A) 
B) Wt CaM  CaM S101D 
0      0.25    0.5    0.75     1        2      4       8 0     0.25    0.5    0.75    1       2       4       8 





by two-fold. Unfortunately, this data is in not in agreement with previous studies by (Corti, et al., 
1999).  The Corti group did not use phosphomimetic CaM Y99E to assess the activity of nNOS, 
but instead phosphorylated CaM using PTK-III kinase in vitro (see at table 1.1). Although PTK-
III targets CaM Tyr 99 for phosphorylation, a small fraction (~15%) of CaM Tyr 138 was also 
phosphorylated in their study. This was determined using ESI-Mass spectroscopy. Nevertheless, 
the author observed a 3 fold increase in nNOS activity by CaM phosphorylated at Tyr 99 and/or 
Y99/Y138. It is very plausible that phosphomimetic residues, employed in this thesis, Y99E and 
Y99E/Y138E of CaM are not mimicking the effects of an actual phosphorylated tyrosine residue 
of CaM. To determine whether the reduction in NOS activity is due to electrostatic interaction 
resulting from the Glu side chain, or changes in the conformation of CaM arising from the CaM 
mutation, future experiments must be performed with CaM mutants containing a substitution of 
Tyr 99 with Gln instead of Glu. Therefore, if a reduction in the nNOS activity by CaM with a 
Gln 99 substitution is equivalent to the one by CaM Glu 99, it can be concluded that the 
phosphomimetic CaM-Y99E does not mimic CaM with phosphorylation at Y99.  It is possible 
that the Corti group may have made a mistake in their analysis. This can be justified by 
examining the crystal structure of Holo-CaM. The phenol group of CaM Y99 is located about 5 




   
Figure 3.3- Structural comparison of the C-terminal domain of Ca2+-CaM.  Structures A) 
and B) represent the C-terminal domain of CaM with Tyr 99 colored in purple with Asp 131, 
133, and 137 colored in green. C) C-terminal domain of wild-type CaM with nNOS peptide 
(colored in blue). Asp 133 is colored in green with Tyr 99 colored in purple and Asp 131 colored 
in yellow. The distance between Asp 133 and Tyr 99 of CaM is 5Å away. The yellow/white 
spheres represent calcium ions. The model was created using coordinates for Holo-CaM 
(Chattopadhyaya et al., 1992) PDB 1CLL and PDB NO60 for CaM with NOS peptide. Models 
were generated using ViewerLite 5.0 (Accelrys).  
 
 
Therefore, the addition of a negatively charged phosphate ion in the vicinity of a 
negatively charged aspartic acid cluster may result in an electrostatic repulsion that disrupts the 
required binding of calcium ion to the 4th EF-hand motif of CaM, thus modifying its entire 
conformation. One way of preventing the 4th EF-hand motif of CaM from binding to calcium 
ions is by substituting the aspartic acid 131 with alanine residue to disrupt the biding of 4th EF-
hand motif to calcium ions (Spratt et al, 2007 b). As a result, CaM that can not bind to calcium 
ion on the 4th EF-hand motif will not be able to fully activate nNOS. This is based on studies by 
Spratt et al,( 2007b). Unfortunately, direct interactions between CaM Y99 and residues of the 
cNOS CaM-binding domain are unknown based on crystal structure of CaM bound to NOS 
CaM-binding domain. It is plausible that Y99 associates with NOS residues outside of the CaM-
binding domain, such as the oxygenase domain. Neither the NADPH nor the cytochrome c assay, 




Tyr 99 ~5 Å 
Wt CaM C-domain  
A B      C 










any of the phosphomimetic CaM proteins when compared to wild-type CaM (Table 3.2). 
However, unlike the eNOS enzyme, where CaM Y99E variants attenuated the enzyme activity 
by two-fold, nNOS was not affected to a significant degree by this phosphomimetic residue 
when in coexistence with other phosphomimetic residues, such as S101D or Y138E. 
Disrupting the native conformation of CaM by phosphorylation to modulate the activity 
of target enzymes could serve many functional purposes in the cell. For example, Tyr 99 
phosphorylation in the cerebral cortex of newborn piglets during hypoxia could serve as a 
defensive mechanism by neurons in response to increased •NO production by nNOS (Mishra et 
al., 2009b).   
On the other hand, CaM Tyr 138 is located 2 Å away from CaM Glu 82 when CaM is 
bound to Ca2+. However, this distance is extended to ~6 Å when CaM is bound to either the 
nNOS or eNOS CaM-binding domain peptide. Therefore, phosphorylation of CaM Y138 should 
not result in a significant change in cNOS activity, although a 30% reduction in •NO synthesis 
by nNOS is observed.  
Binding and structural disturbances between CaM and its target protein upon Camstatin 
binding have already been demonstrated. Camstatin, at 40-fold excess to CaM, can compete with 
NOS for the binding of CaM, even though the binding affinity of CaM to NOS is 40-fold higher 
than it is to Camstatin. Therefore, phosphorylation of CaM may increase the binding affinity of 
CaM to Camstatin or reduce CaM’s affinity for NOS. With this in mind, we performed several 
Gel Shift Mobility Assays to analyze the binding stoichiometry of Camstatin to some of the 
previously studied phosphomimetic CaM proteins (S101D and T79D/S101D). Originally we 
attempted to saturate CaM with 8-fold excess Camstatin; however, this was not the case. The low 
binding affinity of Camstatin to wild-type CaM is observed when CaM could not be saturated by 
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40-fold excess Camstatin (Figure 3.2). This supports the previous notion made earlier that the 
binding affinity of Camstatin to CaM is very weak and that phosphorylation of CaM in the C-
terminal domain may increase the binding affinity. 
 
The next approach is to investigate the effect phosphomimetic CaM variants with 


























Calmodulin (CaM) is one of the most abundant proteins in the eukaryotic cell, 
constituting up to 1.0% of the total eukaryotic cell proteins (Means et al, 1982). Depending on 
the cell cycle and the cell type, CaM is observed to localize in both the cytoplasm and the 
nucleus of eukaryotic cells. For instance, it has been determined that CaM proteins, in smooth 
muscle cells, are localized in the cytoplasm during cell resting state (Thorogate et al, 2004) 
Changes in the localization of CaM are caused by spikes of intracellular calcium concentrations 
in response to a stimulus (Zavortink et al., 1983; Teruel et al., 1999). Stimulation of the cell 
followed by an influx of the calcium ions results in the translocation of CaM into the nucleus by 
an unknown shuttle protein (Thorogate et al., 2007).  
Little is know about the spatial distribution of CaM within the cell. Nonetheless, Torok’s 
group was able to illustrate the spatial distribution of CaM in sea urich zygote before and after 
fertilization (Torok et al., 2002). In their study, CaM was observed to localize in the nucleus of 
the zygote prior fertilization, and on the chromosomes during the fertilization process (Torok et 
al., 2002).  
Persechini and collaborators revealed that CaM was limiting in the cell with an estimated 
concentration 20 μM (Persechini et al, 2002). Changes in concentration and spatial distribution 
of CaM inside the cell can play a vital role in modulating cellular processes. For example, a 
decrease in CaM concentration in the cell can arrest the cell cycle at the G1 phase (Persechini et 
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al., 2002). Furthermore, the limited amount of CaM in the cell causes competition between 
target-proteins and permits selective activation of cellular processes. Post-translational 
modification of either target-proteins or CaM itself can have a great impact on CaM dependent 
signaling pathways. For instance, phosphorylation of CaM can change its binding affinity for 
certain target-proteins, thus allowing it to selectively activate various enzymes or cellular 
processes (Persechini et al, 2002). 
 
4.1.1 Apo-CaM in mammalian cells 
For decades, it was believed that CaM can only bind to its target protein in a calcium 
replete-form. However, current research has emphasized the functionally important role of Apo-
CaM. In addition to the 8 known cytoplasmic Apo-CaM target proteins, Apo-CaM can also 
associate with the cell membrane and other cellular compartments, such as the nucleus, 





Figure 4.1- Schematic representation of the compartmental association of Apo-CaM within 




  It is reported that 99% of CaM in the adult cardiac myocyte is bound to target proteins, 
either in its Apo-form or with some calcium bound to it (Maier et al., 2006). Upon calcium 
induction, Apo-CaM favors the binding and activation of localized cytoplasmic or membrane 
target proteins in its vicinity (Maier et al., 2006). Intrigued by these observations, we decided to 
investigate the uptake and distribution of Apo-CaM in various mammalian cell lines. This work 
was to be accomplished by labeling the Apo-CaM protein with a fluorescent marker and 
coupling it to cell-membrane translocation vector. 
As a result, Apo-CaMs were generated by substituting an aspartic acid in the EF-hand 
motif with an alanine to prevent the binding of calcium ions (Figure 4.2) (Table 4.1).  
 
Figure 4.2- Schematic diagram of CaM protein. Key calcium binding residues in each EF-
hand motif is colored in red. Modification of each aspartic residue to alanine prevents the 









Table 4.1- A list of Apo-CaM mutants.  
CaM mutant α Category  Type of Modification 
CaM12 Partial Calcium-deficient D21A, D56A 
CaM34 Partial Calcium-deficient  D93A, D131A 
CaM1234 Apo-CaM D21A, D56A D93A, D131A 
 
α These proteins have also been modified to contain two Cysteine (Cys 34 and Cys 110) residues for fluorescence 
labeling and TAT coupling. The numerical values preceding “CaM” correspond to the EF-hand motifs that are not 
capable of binding to calcium ions. For example, CaM12 can only bind to calcium ions in the 3rd and 4th EF-hand of 
the CaM protein. 
 
Furthermore, to monitor protein trafficking of Apo-CaMs in the cell, a cysteine residue 
was incorporated (T34C) for labeling purposes. In this case, Apo-CaM proteins were labeled 




Figure 4.2.1- Fluorescent probes. These probes were used in the labeling of CaM proteins 
(Texas Red and TRITC) and TAT peptide (FITC) 
  
In addition, a second cysteine residue (C110) was also incorporated in CaM proteins to 
serve as a reactive site for TAT coupling. TAT peptides will serve as a delivery system to 
introduce Apo-CaMs into the cytoplasm of mammalian cells with great efficiency and low 
Texas Red FITC 




cellular toxicity (see Table 1.2 for TAT peptide sequence). However, since TAT peptides contain 
a nuclear localization sequence (NLS) that shuttles attached cargo molecules to the nucleus, it 
was necessary to couple peptide Apo-CaMs to TAT peptide by a disulfide bridge. The 
internalization of the Apo-CaM-TAT fusion protein in the cytoplasm will result in the reduction 
of the disulfide bridge by intercellular glutathione, thus liberating CaM from the TAT peptide 
(Fischer et al., 2005). This modification should allow Apo-CaM to freely interact with other 
cellular compartments and proteins upon cellular internalization, while permitting TAT peptide 
to continue on its course to the nucleus.  
The TAT peptides used in this study were also labeled with a fluorescein isothiocyanate 
(FITC) fluorophore (Figure 4.2.1), for tracking purposes (Figure 4.3).  
 
 
Figure 4.3- Illustration of labeled TAT peptide-CaM fusion protein. The color of each 
component appears in parenthesis after its identification: aminohexanoyl linker, represented as 
ahx (blue), FITC probe (green), TAT peptide (yellow), CaM (grey) and Texas Red probe (red). 
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Three different cell lines were employed in this investigation to monitor fluorescently 
active CaM proteins intracellularly. These cell lines included mouse Embryonic Stem Cells 
(mESCs), Human Neuronal Glioma Cells (HNGCs), and Human Umbilical Vein Endothelial 
Cells (HUVECs). These cell lines were chosen because they differ in their functional 
specialization and they were made readily available to us by our collaborator, Dr. E. Jervis 
(Chemical Engineer, University of Waterloo). In addition, using functionally different cells 
would allow us to compare and contrast protein trafficking of Apo-CaM in cells with different 
cell cycles and metabolic properties. 
To maximize the product yield of the CaM-TAT fusion construct, an amine reactive 
Tetramethyl Rhodamine Iso-Thiocyanate (TRITC) fluorophore was substituted for the Texas 
Red dye (Figure 4.2.1). This substitution liberated a second cysteine residue in CaM that was 
used to increase TAT-CaM coupling efficiency by reducing the number of purification steps.   
 
4.2 Experimental procedures 
4.2.1 Protein expression and purification of CaM 
Apo-CaM proteins (CaM1234, CaM12 and CaM34), a generous gift from Dr. J. Adelman, 
were modified to contain two thiol groups by substituting T34 and T110 with cysteine residue 
for Texas Red labeling and TAT-FITC coupling. The protein expression and purification 
procedure for Apo-CaM is summarized in section 2.2.2.  ESI-MS and SDS-PAGE analysis was 






4.2.2 Rhodamine labeling of CaM  
CaM proteins and rhodamine dyes (Texas Red or TRITC) were transferred into labeling 
buffer (0.1 M sodium bicarbonate, pH 9.0) via gel filtration using a Sephadex G-25 PD-10 
column (Amersham Biosciences), as previously described by Lang et al. (2005), to remove 
traces of Tris-buffer and DTT. The concentrations of the CaM proteins were estimated to be 
about 8 mg/mL based on UV spectroscopy analysis. The labeling process was performed as 
described by the manufacturer (Molecular Probes, Eugene, OR, USA) with the exception that for 
every mole of CaM present in the reaction, 2-3 moles of TRITC was added. Excess TRITC was 
removed via gel filtration using a Sephadex G-25 PD-10 column (Amersham Biosciences), 
equilibrated with 100 mM phosphate buffer, pH 7.4, to ensure that all non-covalently linked dye 
was removed from the labeled CaM proteins. The flow-through was collected in 500 µL 
fractions. Fractions that contained CaM were pooled and analyzed by ESI-MS to confirm 
successful TRITC or Texas Red labeling of each CaM protein. The thioethers in CaM do not 
react with amine reactive TRITC or Texas Red molecules. The remainder of the pooled fraction 
was stored at -80ºC for subsequent experiments. 
 
4.2.3 CaM-TAT coupling  
The TAT-FITC peptide (FITC-AHX-YGRKKRRQRRRGGGC[NPYS]-NH2; MW 2490 
Da) was purchased from ANASPEC (Fremont, California, USA). A coupling efficiency of 100% 
for TAT-FITC and free thiol groups of CaM requires that the CaM protein samples be 
completely devoid of Dithiothriotol (DTT) and Tris buffer. This was achieved by transferring 
CaM proteins into a coupling buffer (100 mM Phosphate buffer, pH 6.3) by gel filtration using a 
Sephadex G-25 PD-10 column (Amersham Biosciences). CaM is then reacted with 4 fold excess 
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TAT-FITC to CaM protein to ensure maximum coupling efficiency. The reaction was carried out 
at room temperature for 12 hours on a shaker. The sample was then washed three times with 
deionized water using a 10 kDa cut-off spin column (Pall Scientific) to remove excess unbound 
FITC-TAT. ESI-MS was used to confirm FITC-TAT labeling of each CaM protein. 
 
4.2.4 Fluorescence imaging of live cells 
mESCs, HUVEC, and HNGCs were adhered to the surface of gap chambers in 500 μL 
medium (DMEM/F12). Added to each separate chamber was incubated with one of the following 
samples: CaM-TRITC, TAT-FITC, TRITC-Lysine, and FITC-TAT-CaM-TRITC with a total 
concentration of 20 μM. The chambers were incubated for 2 hours at 37˚C. Following 
incubation, the cells were washed twice with 500 μL of growth media (Neurobasal Expansion 
21103 or DMEM) and imaged at 400X magnification using a fluorescence microscope (Zeiss 
Axiovert 200M) to detect FITC and TRITC fluorescence. The FITC fluorophore was excited at 
485 ± 20 nm and detected with a 515-565 nm bandpass filter. The TRITC or Texas Red 
fluorophore was excited at 560 ± 50 nm and detected with a 645 ± 75 nm bandpass filter. 
  
 
4.2.5 PREP-4 purification procedure 
Unfortunately, it was discovered that the acquired images of all three cells ( mESC, 
HUVEC, HNGC) incubated with rhodamine labeled CaM were contaminated with non-specific 
TRITC/Texas Red emission from within the cells. From previous experiments, involving 
fluorescent imaging of cells incubated with FITC-labeled CaM, we know that CaM does not 
enter the cell without a translocation vector (Figure 4.4). Hence, cells incubated with CaM- 
Texas Red (a rhodamine dye) or TRITC dye were not expected to fluoresce, nevertheless, they 
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did (Figure 4.3.1). A possible explanation for this may be that a significant amount of TRITC 
and Texas Red molecules broke free from the CaM proteins and became internalized by the cell 
(Rashid and Horobin, 1990).  
 
 
Figure 4.3.1- Cell imaging of HUVECs-2. HUVECs imaged at 400X magnification 2 hours 
after CaM-Texas Red incubation (20 µM) at 37ºC. The cells were washed twice with 500 µL of 
medium to remove CaM-Texas Red proteins and then re-suspended with 500 µL of fresh 
medium (DMEM by Invitrogen). Fluorescence emission of Texas Red is observed within the 
cell. 
 
Alternatively, the rhodamine dyes may have promoted the shuttling of CaM across the 
cell membrane. This can be tested by labeling CaM with both FITC and Rhodamine probe. 
Therefore, if a co-localized of FITC and rhodamine fluorescence emission is observed, we can 
make a conclusion that the rhodamine dye is acting as shuttle vector since we know that free 
FITC probe can permeate the cell membrane  and that the observed FITC emission from the cell 
has to be due to the internalization of CaM by rhodamine probes.  




Figure 4.4- Cell imaging of HUVECs. HUVECS were imaged at 400X magnification, two 
hours after FITC-CaM (40 uM) incubation. The cells were washed twice with 500 µl of DMEM 
medium to remove unbound CaM-FITC residues and then overlaid with 500 µl of fresh DMEM 
media (Invitrogen), The fluorescence FITC emission is observed form the chambers indicating 
that the cells did not uptake CaM-FITC protein. 
 
In an attempt to eliminate the non-specific fluorescence of TRITC, a protocol was 
devised to remove free residual rhodamine molecules from the CaM-TRITC samples. The 
procedure consisted of a 4-step purification process, referred to as PREP-4 in this thesis. Step 
one employed size exclusion chromatography in a Sephadex G-25 PD-10 column (Amersham 
Biosciences) with a 10 kDa molecular weight cut-off to separate TRITC-CaM (Mw ~18000 
g/mol) from free TRITC molecules (Mw ~ 500 g/mol). In this stage excess TRITC dye is 
localized at the top of the column (Figure 4.5 A) The collected eluate was then mixed with a 
hydrophobic adsorbent mesh (non-polar polystyrene Biobeads SM-2; Biorad) for 30 minutes in 
10 mM EDTA. EDTA serves to chelate calcium from CaM to prevent non-specific binding of 
TRITC probe to the hydrophobic pockets of CaM. Meanwhile, the beads capture free TRITC 
from the sample by hydrophobic interactions. The supernatant was collected from the 
hydrophobic adsorbent mesh, which turned pink, indicating that the dye had bound to it (Figure 
4.5 B). In the third step, the collected supernatant was transferred onto a phenyl sepharose resin 
column, equilibrated with buffer C (10mM Tris-HCl, 10 mM EDTA, pH 7.5 @ 4oC). Phenyl 





sepharose resin can only bind to free TRITC probes in the presence of EDTA by preventing the 
exposure of CaM’s hydrophobic pockets that is required for the binding of CaM to the resin 
(Figure 4.5 C). A 10 ml fraction was collected from the column and loaded onto a 15 mL Viva 
Spin column with a 10 kDa molecular weight cut-off and concentrated to a final volume of 1 mL. 
The color pink was not observed in the effluent at this stage, indicating that the sample was free 
of unbound dye (Figure 4.5). The purified sample was then loaded into a gap chamber, 
containing 106 HNGCs, at a final concentration of 20 μM TRITC-CaM, and incubated for 1 hour 
at 37 ºC. The cells were then washed twice with 500 μL of neuronal basal media and imaged 
with a fluorescent microscope (Zeiss Axiovert 200M) at 400X magnification. 
 
Figure 4.5 - Prep-4 purification of CaM-TRITC. A-B denotes the four steps performed to 
eliminate unbound TRITC molecules from CaM-TRITC sample. A) Employs the use of a gel 
filtration gravity column; B) utilization of hydrophobic binding beads; C) hydrophobic binding 
resin is used to remove free TRITC; D) gel filtration spin column is used to further purify the 




A- Sephadex G-25 
10 kDa cut-off 
B-Adsorbent 
beads 
C-Phenyl sepharose D-Viva Spin column 
10 kDa cut-off 
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4.3 Results  
 
4.3.1 Characterization of mutant CaM proteins 
The purity of CaM was determined to be over 95% homogeneous by SDS-PAGE analysis 
(Figure 4.6). The actual molecular weight of Apo-CaM protein was confirmed to be the same as 
the predicted theoretical weight by ESI-MS (Table 4.2). The labeling efficiency of CaM T110C 
with TRITC fluorophore was greater than 100%, as assessed by ESI-MS (Figure 4.7A). A 
fraction of CaM T110C had two to three TRITC fluorophores attached to it. Coupling efficiency 
of TRITC-CaM T110C with TAT-FITC was determined to be 100% by ESI-MS analysis, as 
shown in Figure 4.7 B and Table 4.2.  
 
 
Figure 4.6- 15% SDS-PAGE analysis of purified Apo-CaM proteins.   
A 50 μg sample of each purified CaM protein was loaded with standard SDS-PAGE loading 
buffer containing 1 mM EDTA. Lane 1, low molecular mass protein standard (GE Healthcare); 







Table 4.2 Masses of un-labeled and labeled Apo-CaM proteins  
      
                      Mass (Da)  
     
     
  Observed Theoretical  
 CaM proteins     
   
CaM T110C 16711 16712 
   
Calcium Deficient CaMs   
CaM 12-T34C/T110C 16618 16620 
CaM 34-T34C/T110C 16618 16620 
CaM 1234-T34C/T110C 16533 16534 
 
Labeled CaM   
TRITC-CaM T110C  17151 17153 
   
TRITC-CaM T110C-TAT-FITC 19928.5            19930 
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A   
B  
Figure 4.7- ESI-Mass spectroscopy of CaM. Mass spectral data for A) CaM T110C-TRITC, 
showing 1, 2 and 3 TRITC fluorophores coupled to it, and B) CaM T110C-TRITC-TAT-FITC 
protein variants coupled with a single TAT-FITC peptide.  
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4.3.2 Fluorescence imaging of live cells 
mESCs, HUVECs and HNGC were imaged using a fluorescence microscope at 400X 
magnification after FITC-TAT peptide addition (Figure 4.8). Based on the acquired FITC 
fluorescence data, HNGC was the only cell line that showed significant association with TAT 
peptides. The mESCs and HUVECs only displayed FITC fluorescence in dead or dying cells. 
However, it was too difficult to distinguish between internalized FITC-TAT peptide and 
membrane associated FITC-TAT peptide using this technique. In future experiments, it would be 
of value to perform a mild trypsin (1mg/mL) treatment on the cells to remove non-specific 
binding of TAT peptide to cell membrane constituents, prior to imaging (Richard et al., 2003). 
Also, confocal microscopy can aid in confirming the localization of TAT peptide, relative to the 
















   Bright Field Imaging                Fluorescence Imaging 
 
Figure 4.8- Cell imaging of mammalian cells. Images at 400X magnification of HNGCs, 
HUVECs, and  mESCs two hours after FITC-TAT incubation (20 µM). The cells were washed 
twice with 500 µL of DMEM medium to remove unbound TAT-FITC residues and then overlaid 
with 500 µL of fresh DMEM medium (Invitrogen, Carlsbad, California).  
 
 
                    
 
4.3.3 Fluorescence imaging of live cells with PREP-4 purification process 
HNGCs incubated with 20 μM TRITC-CaM after carrying out the PREP-4 purification is 
still contaminated with free rhodamine, as TRITC emission was detected with the fluorescence 
microscope (Figure 4.9). It is still unclear as to whether the observed fluorescence in the 
acquired images is derived from unbound TRITC probe or from CaM-TRITC in the cell. In 
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future experiments, solving this conundrum entail labeling CaM with both TRITC and FITC 
probes, and identifying their localization with respect to the HNGCs. Since previous experiments 
have shown that the FITC probe can not be internalized by the cells, co-localization of both 
fluorescence emissions will be an indication that the TRITC probe is acting as a shuttle, 
delivering CaM into the cell. 
 
 
Bright Field Imaging                         Fluorescence Imaging 
 
   




Figure 4.9- Cell imaging of HNGCs with Prep-4 CaM-TRITC. Images at 400X magnification 
of HNGCs, two hours after CaM-TRITC incubation (40 µM).  A) TRITC-CaM purified by the 
PREP-4 method, and B) control cell sample (without TRITC-CaM). The cells were washed twice 
with 500 µL of basal medium to remove unbound TRITC-CAM residues and then overlaid with 











Of the four cell lines tested for TAT-FITC peptide internalization, only the HNGCs 
exhibited FITC emission (Figure 4.8). However, it was never confirmed as to whether the 
observed FITC emission within the cells resulted from TAT internalization or an artifact of non-
specific interactions between TAT and cell membrane constituents.  Nonetheless, HUVECs and 
mESCs were not capable of up-taking FITC-TAT peptide into the cell. Although TAT peptide 
has been previously established as a CPP capable of penetrating all cell types, recent studies have 
emerged with contradicting evidence and propose that different cell types, differing in their 
membrane composition, also differ in the degree of interaction with TAT (Fonseca et al., 2009). 
Further complicating things, many reported results contain artifacts arising from cell fixation 
procedures that result in the permeabilization of the cell membrane and passive entry of TAT 
into the cell (Fischer et al., 2005). It has been reported that thiol/disulfide exchange reactions can 
occur between CPP residues and thiols on the cell-surface, promoting CPP internalization 
(Aubry et al., 2009). It is possible that the TAT-FITC peptide used in this study may be 
interacting with cell membrane thiol groups via a cysteine residue, leading to its entry into the 
cell.  
Another source of contamination, hindering this study, was caused by the rhodamine 
fluorophore. Despite the notion that TRITC- and Texas Red-labeled CaM is impermeable to the 
cell membrane, non-specific rhodamine emission was detected within the cell, even after several 
wash steps (Figure 4.9). Additional purification steps are required to avoid this contamination; 
otherwise, it may be necessary to resort to the use of a different fluorophore label that does not 
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